datetime,headline,summary,related,lang,source
2020-12-07 12:00:00,ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting,"LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced updated clinical data from its two lead programs, loncastuximab tesirine (Lonca) and camidanlumab tesirine (Cami), which were presented at the 62nd American Society of Hematol",ADCT,en,Business Wire
2020-11-20 16:51:00,ADC Therapeutics meldet Annahme der Biologics License Application sowie beschleunigtes Zulassungsverfahren für Loncastuximab-Tesirin zur Behandlung des rezidivierten oder refraktären diffus großzelligen B-Zell-Lymphoms durch die FDA,"LAUSANNE, Schweiz--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie, das Vorreiter bei der Entwicklung und Vermarktung von hochwirksamen und zielgerichteten Antikörper-Wirkstoff-Konjugaten (AWK) für Patienten mit hämatologischen Malignomen und soliden Tumoren ist, gab heute bekannt, dass die U.S. Food and Drug Administration (FDA) ihre Biologics License Application (BLA) für Loncastu",ADCT,de,Business Wire
2020-11-13 08:06:00,ADC Therapeutics veröffentlicht Finanzergebnisse für das dritte Quartal 2020 und präsentiert aktuelle Highlights seiner Geschäftsentwicklung,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Spezialisierung auf Onkologie u",ADCT,de,Business Wire
2020-11-12 12:00:00,ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights,"ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of hig",ADCT,en,Business Wire
2020-11-10 12:15:00,ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference,"LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that Chris Martin, Chief Executive Officer, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 am ET. A live webca",ADCT,en,Business Wire
2020-11-05 21:16:00,ADC Therapeutics gibt am 12. November 2020 in einer Telefonkonferenz die Finanzergebnisse für das dritte Quartal 2020 bekannt,"LAUSANNE, Schweiz--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt Onkologie und Vorreiter in der Entwicklung und Vermarktung von hochwirksamen und zielgerichteten Antikörper-Wirkstoff-Konjugaten (AWK) für die Behandlung von Patienten mit hämatologischen Malignomen und soliden Tumoren, meldet heute, dass es am Donnerstag, den 12. November 2020 um 8.30 Uhr ET (US-Ostküsten-Zeit) eine Telefonkonfer",ADCT,de,Business Wire
2020-11-05 12:15:00,"ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020","LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, November 12, 2020 at 8:30 am ET to report financial results for the third quarter ended September 30, 2020 a",ADCT,en,Business Wire
2020-10-31 00:13:00,Genmab und ADC Therapeutics melden erweiterte Vereinbarung für Camidanlumab Tesirin (Cami),"Genmab A/S (Nasdaq: GMAB) und ADC Therapeutics SA (NYSE: ADCT) gaben heute den Abschluss eines geänderten Abkommens bekannt, demzufolge ADC Therapeuti",ADCT,de,Business Wire
2020-10-23 08:00:52,ADC Therapeutics (NYSE:ADCT) Stock Rating Upgraded by Zacks Investment Research,"Zacks Investment Research upgraded shares of ADC Therapeutics (NYSE:ADCT) from a sell rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports. According to Zacks, “ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from […]",ADCT,en, Dakota Financial News
2020-10-23 04:00:50,ADC Therapeutics (NYSE:ADCT) Lifted to “Hold” at Zacks Investment Research,"Zacks Investment Research upgraded shares of ADC Therapeutics (NYSE:ADCT) from a sell rating to a hold rating in a research note published on Tuesday, Zacks.com reports. According to Zacks, “ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies […]",ADCT,en,Dispatch Tribunal
2020-10-21 04:10:56,ADC Therapeutics (NYSE:ADCT) Upgraded to “Hold” by Zacks Investment Research,"Zacks Investment Research upgraded shares of ADC Therapeutics (NYSE:ADCT) from a sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, “ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from […]",ADCT,en,The Lincolnian
2020-10-21 01:10:54,ADC Therapeutics (NYSE:ADCT) Upgraded to Hold at Zacks Investment Research,"Zacks Investment Research upgraded shares of ADC Therapeutics (NYSE:ADCT) from a sell rating to a hold rating in a research note released on Tuesday morning, Zacks.com reports. According to Zacks, “ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological […]",ADCT,en,Daily Political
2020-10-16 11:15:07,"The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Kronos Bio Inc (NASDAQ: KRON ) (IPOed Friday) Larimar Therapeutics Inc (NASDAQ: LRMR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Twist Bioscience Corp (NASDAQ: TWST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 15) ADC Therapeutics SA (NYSE: ADCT ) Alector Inc (NASDAQ: ALEC ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aziyo Biologics Inc (NASDAQ: AZYO ) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq Wednesday) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Dyne Therapeutics Inc (NASDAQ: DYN ) Pandion Therapeutics Inc (NASDAQ: PAND ) ProQR Therapeutics NV (NASDAQ: PRQR ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) (provided a strategic and corporate update) Uniqure NV (NASDAQ: QURE ) Stocks In Focus Zogenix Presents Data Showing Durability of Response For Seizure Drug Zogenix, Inc. (NASDAQ: ZGNX ) released interim data from open-label extension trial, showing substantial seizure reductions were maintained when treated with Fintepla oral solution for up to two years.",ADCT,en,Benzinga
2020-10-09 20:15:00,ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares,"LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the underwriters in its recent upsized public offering of 6,000,000 common shares, which closed on September 28, 2020, have exercised in full their option to purchase an additional",ADCT,en,Business Wire
2020-09-22 04:33:00,ADC Therapeutics stellt Antrag auf Biologikazulassung bei der US-amerikanischen Food and Drug Administration für Loncastuximab Tesirin zur Behandlung von rezidiviertem oder refraktärem diffus großzelligem B-Zell-Lymphom,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie, das",ADCT,de,Business Wire
2020-09-17 11:15:00,ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020,"LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the presentation of an on-demand e-poster titled “First-in-Human Study of Camidanlumab Tesirine (ADCT-301, Cami), an anti-CD25 Targeted Therapy in Patients with Advanced Soli",ADCT,en,Business Wire
2020-09-10 11:35:00,ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers,"LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that preclinical data related to camidanlumab tesirine (Cami, formerly ADCT-301) has been published in the Journal for ImmunoTherapy of Cancer, the online journal of the Soci",ADCT,en,Business Wire
2020-09-05 18:54:00,ADC Therapeutics donne un avis de renonciation partielle aux restrictions conformément à la règle 5131 de la FINRA,"LAUSANNE, Suisse--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE : ADCT), a annoncé aujourd'hui que Morgan Stanley & Co. LLC et BofA Securities, Inc., les principaux co-syndicataires de la récente introduction en bourse de la société, libèrent une restriction de blocage concernant 105 000 actions ordinaires détenues par A.T. Holdings II Sàrl, une filiale de Peter B. Corr et Stephen Evans-Freke qui sont membres du conseil d'administration de la société, dans le cadre d'une transaction en bloc d'",ADCT,fr,Business Wire
2020-08-19 06:42:00,ADC Therapeutics gibt Finanzergebnisse für das zweite Quartal 2020 und Highlights zur jüngsten Geschäftsentwicklung bekannt,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt Onkologie und Vorre",ADCT,de,Business Wire
2020-08-18 11:15:00,ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights,"LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today reported financial results for the second quarter ended June 30, 2020 and provided recent business highlights. “ADC Therapeutics progressed rapidly this past quarter, and we are contin",ADCT,en,Business Wire
2020-07-23 07:00:00,Synaffix Announces Expansion of Collaboration with ADC Therapeutics,"AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies. Under the expanded collaboration, ADC Therapeutics has been granted non-exclusive rights for two additional programs,",ADCT,en,Business Wire
2020-07-17 18:53:00,ADC Therapeutics annonce qu'un premier dosage a été déterminé en phase II de l'essai clinique pivot LOTIS 3 du loncastuximab tésirine (Lonca) combiné à l'ibrutinib,"LAUSANNE, Suisse--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), une société de biotechnologie spécialisée dans l'oncologie au stade clinique avancé, pionnière du développement et de la commercialisation de conjugués anticorps-médicaments («antibody drug conjugates - ADC») très puissants et très ciblés destinés aux patients atteints d'hémopathies malignes et de tumeurs solides, a annoncé aujourd'hui la détermination du premier dosage dans le cadre de l'essai pivot de phase II de LOTIS 3, un",ADCT,fr,Business Wire
2020-07-17 11:15:00,ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib,"LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in com",ADCT,en,Business Wire
2020-07-06 20:44:00,ADC Therapeutics annonce que l'Agence américaine des produits alimentaires et médicamenteux a levé la suspension clinique partielle dont faisait l’objet l’étude clinique pivot de Phase 2 sur le camidanlumab tésirine,"ADC Therapeutics SA (NYSE:ADCT), une société de biotechnologie spécialisée dans l’oncologie au stade clinique avancé, pionnière du développement et de",ADCT,fr,Business Wire
2020-07-06 12:10:02,FDA halts enrollment in mid-stage study of ADC Therapeutics' camidanlumab tesirine (NYSE:ADCT),The FDA has placed a partial clinical hold on a pivotal Phase 2 clinical trial evaluating ADC Therapeutics' (NYSE:ADCT) antibody-drug conjugate camidanluma,ADCT,en,Seeking Alpha
2020-07-05 19:19:55,ADC Therapeutics Completes $267M IPO | FinSMEs,"ADC Therapeutics (NYSE:ADCT), a Swiss and US late clinical-stage oncology-focused biotechnology company, raised $267.6m through its IPO",ADCT,en,FinSMEs
2020-07-02 12:21:23,"The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.","ABBV,ADCT",en,Benzinga
2020-07-01 12:12:04,"The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) ADC Therapeutics SA (NYSE: ADCT ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) ( announced agreement with the FDA regarding Phase 2 study of Parkinsonian disorder drug) Calliditas Therapeutics AB ADR (NASDAQ: CALT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) - partner Seattle Genetics, Inc. (NASDAQ: SGEN ) announced positive results for antibody-drug conjugate for cervical cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) ( reacted to a positive analyst action) Legend Biotech Corp (NASDAQ: LEGN ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Pliant Therapeutics Inc (NASDAQ: PLRX ) ResMed Inc. (NYSE: RMD ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) (announced launch of Twist Respiratory Virus Research Panel for detecting a range of respiratory diseases) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 30) Brickell Biotech Inc (NASDAQ: BBI ) Iterum Therapeutics PLC (NASDAQ: ITRM ) (announced $15 million registered offering) Qualigen Therapeutics Inc (NASDAQ: QLGN ) Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN ) VIVUS, Inc. (NASDAQ: VVUS ) Stocks In Focus T2 Biosystems Pre-Announces In-Line Q2 Revenues, Launches COVID-19 Test In US T2 Biosystems Inc (NASDAQ: TTOO ) announced the U.S. launch of the T2SARS-CoV-2 Panel, its COVID-19 molecular diagnostic test.",ADCT,en,Benzinga
2020-06-30 14:42:03,"ADC Therapeutics : New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO | MarketScreener","VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its… | June 30, 2020",ADCT,en,MarketScreener
2020-06-24 12:07:18,"The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.","ACAD,ADCT",en,Benzinga
2020-06-23 11:57:59,"The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout","The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.",ADCT,en,Benzinga
2020-06-19 11:41:54,"The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alpine Immune Sciences Inc (NASDAQ: ALPN )( announced a licensing agreement with AbbVie Inc (NYSE: ABBV ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Castle Biosciences Inc (NASDAQ: CSTL ) Cytokinetics, Inc. (NASDAQ: CYTK ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Neubase Therapeutics Inc (NASDAQ: NBSE ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Ovid Therapeutics Inc (NASDAQ: OVID ) Passage Bio Inc (NASDAQ: PASG ) Pliant Therapeutics Inc (NASDAQ: PLRX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Royalty Pharma plc (NASDAQ: RPRX ) (IPOed Monday) Sarepta Therapeutics Inc (NASDAQ: SRPT )(announced a licensing agreement with Selecta Biosciences Inc (NASDAQ: SELB ) for licensing the latter's immune tolerance platform, ImmTOR for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TELA Bio Inc (NASDAQ: TELA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 18) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Stocks In Focus Mylan Wins Patent Lawsuit Against Biogen With Respect To Multiple Sclerosis Drug Mylan NV (NASDAQ: MYL ) said the U.S.","ABBV,ADCT",en,Benzinga
2020-06-15 11:06:00,ADC Therapeutics veröffentlicht belastbare Daten aus der zulassungsrelevanten klinischen Phase-II-Studie und der klinischen Phase-I/II-Kombinationsstudie mit Loncastuximab-Tesirin (Lonca) (...),"LAUSANNE, Schweiz--(BUSINESS WIRE)-- ADC Therapeutics veröffentlicht belastbare Daten aus der zulassungsrelevanten klinischen Phase-II-Studie und der klinischen Phase-I/II-Kombinationsstudie mit Loncastuximab-Tesirin (Lonca) bei Patienten mit rezidiviertem oder refraktärem diffus großzelligem B-Zell-Lymphom ADC Therapeutics SA (NYSE:ADCT), ein in der klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt Onkologie und Vorreiter in der Entwicklung und Vermarktung von Antikörper-",ADCT,de,Business Wire
2020-06-15 11:06:00,ADC Therapeutics annonce la consolidation des données de l'essai clinique pivot de Phase 2 et de l'essai clinique combiné de Phase 1/2 du loncastuximab tesirine (Lonca) (…),"LAUSANNE, Suisse--(BUSINESS WIRE)-- ADC Therapeutics annonce la consolidation des données de l'essai clinique pivot de Phase 2 et de l'essai clinique combiné de Phase 1/2 du loncastuximab tesirine (Lonca) chez des patients atteints d'un lymphome diffus à grandes cellules B récidivant ou réfractaire ADC Therapeutics SA (NYSE: ADCT), une société de biotechnologie axée sur l'oncologie au stade clinique, qui mène le développement et la commercialisation de la prochaine génération de conjugués anti",ADCT,fr,Business Wire
2020-06-12 06:30:00,ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma,"LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, today announced maturing data from LOTIS 2, a pivotal Phase 2 clinical trial of loncastuximab tesirine (Lonca, formerly ADCT-402) in patients with relapsed or refractory diffuse large B-cell lymp",ADCT,en,Business Wire
2020-06-05 21:03:00,ADC Therapeutics organise une conférence téléphonique sur les données des essais cliniques du Loncastuximab Tésirine (Lonca) à présenter au congrès annuel virtuel de l'Association européenne d'hématologie,"LAUSANNE, Suisse--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), une société de biotechnologie spécialisée dans l'oncologie au stade clinique avancé, pionnière du développement et de la commercialisation de conjugués médicamenteux d'anticorps très puissants et ciblés pour les patients souffrant d'hémopathies malignes et de tumeurs solides, a annoncé aujourd'hui qu'elle organisera une conférence téléphonique en direct et en webdiffusion le vendredi 12 juin 2020 à 8h30 EDT pour présenter les d",ADCT,fr,Business Wire
2020-06-05 18:29:00,ADC Therapeutics veranstaltet Telefonkonferenz zur Präsentation von Daten aus klinischen Studien mit Loncastuximab Tesirin (Lonca) auf dem virtuellen Jahreskongress der EHA,"LAUSANNE, Schweiz--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt Onkologie und Vorreiter in der Entwicklung und Vermarktung von hochwirksamen und zielgerichteten Antikörper-Wirkstoff-Konjugaten (AWK) für die Behandlung von Patienten mit hämatologischen Malignomen und soliden Tumoren, kündigte heute an, am Freitag, dem 12. Juni 2020, um 8:30 Uhr EDT (US-Ostküsten-Sommerzeit) eine Live-Konferenzsc",ADCT,de,Business Wire
2020-05-29 11:22:24,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO )( announced a collaboration study for razuprotafib in COVID-19 treatment) Aileron Therapeutics Inc (NASDAQ: ALRN ) Arca Biopharma Inc (NASDAQ: ABIO ) ( reacted to its planned foray into COVID-19 treatment) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) ChemoCentryx Inc (NASDAQ: CCXI ) GENMAB A/S/S ADR (NASDAQ: GMAB )(announced positive topline Phase 3 data for daratumumab in light-chain amyloidosis) Imara Inc NASDAQ: (IMRA) Liquidia Technologies Inc (NASDAQ: LQDA ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Tenax Therapeutics Inc (NASDAQ: TENX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 28) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Karyopharm to Present Positive Selinexor Data In Multiple Myeloma Patients At ASCO Karyopharm Therapeutics Inc (NASDAQ: KPTI ) announced detailed results from the pivotal Phase 3 BOSTON study that evaluated once-weekly selinexor in combination with once-weekly Velcade and low-dose dexamethasone, or SVd, compared to the standard twice-weekly Velcade plus low-dose dexamethasone, or Vd, in second-line to fourth-line setting in multiple myeloma patients.","ADCT,ABIO",en,Benzinga Feeds
2020-05-27 11:25:23,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.",ADCT,en,Benzinga
2020-05-21 12:01:32,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.",ADCT,en,Benzinga
2020-05-20 12:12:06,"The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) ChemoCentryx Inc (NASDAQ: CCXI ) Evoke Pharma Inc (NASDAQ: EVOK ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Translate Bio Inc (NASDAQ: TBIO ) Twist Bioscience Corp (NASDAQ: TWST ) United Therapeutics Corporation (NASDAQ: UTHR ) VBI Vaccines Inc (NASDAQ: VBIV ) Vermillion, Inc. (NASDAQ: VRML ) Zai Lab Ltd (NASDAQ: ZLAB ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 19) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) Stocks In Focus Myriad Announces FDA Approval For Companion Diagnostic Test For Prostate Cancer Myriad Genetics, Inc. (NASDAQ: MYGN ) said the FDA approved the BRACAnalysis CDx test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza.",ADCT,en,Benzinga
2020-05-19 22:08:00,"ADCT Closes IPO, ALDX To Provide COVID-19 Update, RWLK To Focus On Telehealth",Today's Daily Dose brings you news about ADC Therapeutics' IPO; Aldeyra Therapeutics' COVID-19 drug development update; Bio-Techne's plan to ramp up COVID-19 Test Kit production; ReWalk's telehealth opportunities; after-hours movers and the latest on the number of coronavirus cases.,ADCT,en,RTT News
2020-05-19 20:52:02,ADC THER : Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit Facility with Deerfield | MarketScreener,"ADC Therapeutics SA , a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients… | May 19, 2020",ADCT,en,MarketScreener
2020-05-19 12:33:09,ADC Therapeutics : FormS-8,"As filed with the Securities and Exchange Commission on May 15, 2020 Registration No. 333-__________ UNITED STATES …",ADCT,en,MarketScreener
2020-05-19 12:24:15,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.","ABUS,ADCT",en,Benzinga
2020-05-15 16:05:48,ADC Therapeutics stock soars 56% in trading debut,"ADC Therapeutics S.A. undefined shares rocketed 56% Friday in their trading debut, after the Swiss biotech's initial public offering priced above its…",ADCT,en,MarketWatch
2020-05-15 11:59:13,"No trading floor, no problem. Citadel Securities execs lay out how they're launching billions in new shares with a process adapted on the fly — including an IPO today.","Citadel Securities has handled nine of the 10 initial public offerings held at the New York Stock Exchange since the temporary closure of the floor on March 23. The group that handled the process, known as designated market makers, completely revamped its framework in order to do it entirely remotely. Communication was key. Citadel Securities sent more than 70,000 emails to listed companies in March. And bridge calls were set up between all the parties involved in public debuts. As a result, Citadel Securities was able to execute two remote IPOs on the same day, in addition to a secondary listing, raising just shy of $1 billion via the public markets. While all previous IPOs Citadel Securities handled during the closure were special purpose acquisition vehicles , Friday will be the first remote IPO of an operating company — ADC Therapeutics. Click here for more BI Prime stories. No trading floor? No problem. Citadel Securities' designated market makers, a group that typically operates out of the New York Stock Exchange's trading floor, has managed to keep business up despite the temporary closure of the iconic trading floor for the past two months.",ADCT,en,Business Insider
2020-05-15 11:49:31,"The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allogene Therapeutics Inc (NASDAQ: ALLO )(reacted to ASCO abstract ) Altimmune Inc (NASDAQ: ALT )(announced first-quarter results and update to its COVID-19 vaccine program) BioXcel Therapeutics Inc (NASDAQ: BTAI )( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) Co-Diagnostics Inc (NASDAQ: CODX ) Myokardia Inc (NASDAQ: MYOK ) Repligen Corporation (NASDAQ: RGEN ) Translate Bio Inc (NASDAQ: TBIO ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) Genfit SA (NASDAQ: GNFT ) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) RA Medical Systems Inc (NYSE: RMED )(reacted to first-quarter results) Recro Pharma Inc (NASDAQ: REPH ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN Stocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ: NK ) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.",ADCT,en,Benzinga
2020-05-15 01:48:02,ADC Therapeutics Announces Pricing of Upsized Initial Public Offering | MarketScreener,"LAUSANNE, Switzerland, May 14, 2020 -- ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and… | May 15, 2020",ADCT,en,MarketScreener
